Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ekso Bionics Holdings (EKSO) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Ekso Bionics Holdings (EKSO) over the last 13 years, with Q3 2025 value amounting to 34.02%.

  • Ekso Bionics Holdings' EBITDA Margin rose 289300.0% to 34.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 75.57%, marking a year-over-year decrease of 85400.0%. This contributed to the annual value of 58.74% for FY2024, which is 266300.0% up from last year.
  • As of Q3 2025, Ekso Bionics Holdings' EBITDA Margin stood at 34.02%, which was up 289300.0% from 185.51% recorded in Q2 2025.
  • Ekso Bionics Holdings' 5-year EBITDA Margin high stood at 34.02% for Q3 2025, and its period low was 185.51% during Q2 2025.
  • Its 5-year average for EBITDA Margin is 90.84%, with a median of 78.21% in 2023.
  • Per our database at Business Quant, Ekso Bionics Holdings' EBITDA Margin surged by 4650400bps in 2021 and then tumbled by -1385600bps in 2025.
  • Quarter analysis of 5 years shows Ekso Bionics Holdings' EBITDA Margin stood at 64.62% in 2021, then tumbled by -79bps to 115.49% in 2022, then surged by 32bps to 78.21% in 2023, then surged by 38bps to 48.49% in 2024, then increased by 30bps to 34.02% in 2025.
  • Its EBITDA Margin stands at 34.02% for Q3 2025, versus 185.51% for Q2 2025 and 101.45% for Q1 2025.